eNavvi Expands Nationwide Compound Pharmacy Network, Invites Accredited Pharmacy Partners

Physician-built platform lets U.S. clinicians prescribe vetted, FDA-compliant compounded medications in under 60 seconds, explicitly blocking unapproved products like compounded semaglutide or tirzepatide.

SAN JOSE, Calif., July 21, 2025 /PRNewswire/ -- eNavvi, the cash‑pay digital prescribing platform founded by physicians, today announced the launch of its All‑Specialty Compound Medication Marketplace and a formal call for additional accredited compounding pharmacies to join its network.

For clinicians, the new release means one login to browse pricing and send digital prescription orders for 150 + pre‑formulated compounds and growing. For pharmacy owners, it offers turnkey access to a rapidly growing prescriber base across the entire country.

What Doctors Can Prescribe Today

Dermatology

• Tretinoin 0.05 % / Hydroquinone 6 % Cream – acne & dyspigmentation
• Minoxidil 5 % / Finasteride 0.1 % Topical Solution – androgenic alopecia
• Clobetasol 0.05 % / Salicylic Acid 3 % Ointment – plaque psoriasis

Gastroenterology

• Nifedipine 0.2 % / Lidocaine 5 % Rectal Cream – anal fissures / hemorrhoids

Urology & Men's Health

• Sildenafil 40 mg Sublingual Troche – erectile dysfunction with rapid onset

Pain & Neurology

• Ketoprofen 10 % / Gabapentin 6 % / Cyclobenzaprine 2 % Cream – neuropathic & myofascial pain

"Compounded medications are indispensable for truly personalized care yet ordering them has been mired in fax workflows," said Alex Prevallet, DO, Chief Growth Officer at eNavvi. "We built eNavvi so any clinician—derm, pain, GI, you name it—can click, confirm, and send in under a minute while keeping patients' out‑of‑pocket costs transparent."

Built‑In Safeguards & Compliance

• FDA alignment: eNavvi blocks NDCs and APIs identified on FDA's Bulk Drug Substances List of concern; no compounded GLP‑1 agents (e.g., semaglutide, tirzepatide) are available.
• Vetted partners: Pharmacies must hold multi-state licenses and hold PCAB or NABP Accreditation.
• HIPAA‑secure workflow: End‑to‑end encryption, SOC 2‑aligned controls, and direct EPCS support planned for Q4 2025.

Invitation to Compound Pharmacies

eNavvi is actively onboarding additional 503‑A and 503‑B pharmacies that can:

1. Demonstrate sterile or non‑sterile USP compliance with recent QA audits.
2. Provide transparent, national pricing for cash‑pay scripts.
3. Integrate via API for digital prescription routing.

Interested pharmacies may apply at [email protected].

Immediate Access for Prescribers

Clinicians can start prescribing compounded therapies today—no subscription fees, no credit card required—via:

• Web: https://enavvi.com/results/CompoundDrugs?condition=1
• iOS: Search "eNavvi" in the App Store.

About eNavvi

eNavvi is a physician‑founded digital prescription pad built to make cash‑pay medications affordable and hassle‑free. The platform connects thousands of verified prescribers to a growing nationwide network of pharmacies, delivering price transparency resulting in patient savings compared with retail cash prices.

Learn more at www.enavvi.com.

Media Contact

Teja Pathakota, MD, MBA
Chief Financial Officer, eNavvi Inc.
[email protected] 

SOURCE eNavvi